BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geyer A, Lorenzer C, Gehrig S, Simlinger M, Winkler J, Sami H, Ogris M. Fluorescence- and computed tomography for assessing the biodistribution of siRNA after intratracheal application in mice. International Journal of Pharmaceutics 2017;525:359-66. [DOI: 10.1016/j.ijpharm.2017.02.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chow MYT, Qiu Y, Lam JKW. Inhaled RNA Therapy: From Promise to Reality. Trends Pharmacol Sci 2020;41:715-29. [PMID: 32893004 DOI: 10.1016/j.tips.2020.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Geyer A, Taschauer A, Alioglu F, Anton M, Maier J, Drothler E, Simlinger M, Yavuz S, Sami H, Ogris M. Multimodal Fluorescence and Bioluminescence Imaging Reveals Transfection Potential of Intratracheally Administered Polyplexes for Breast Cancer Lung Metastases. Hum Gene Ther 2017;28:1202-13. [PMID: 28874076 DOI: 10.1089/hum.2017.137] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Okuda T, Toyoda Y, Murakami T, Okamoto H. Biodistribution/biostability assessment of siRNA after intravenous and intratracheal administration to mice, based on comprehensive analysis of in vivo/ex vivo/polyacrylamide gel electrophoresis fluorescence imaging. Int J Pharm 2019;565:294-305. [PMID: 31078647 DOI: 10.1016/j.ijpharm.2019.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Taschauer A, Polzer W, Alioglu F, Billerhart M, Decker S, Kittelmann T, Geppl E, Elmenofi S, Zehl M, Urban E, Sami H, Ogris M. Peptide-Targeted Polyplexes for Aerosol-Mediated Gene Delivery to CD49f-Overexpressing Tumor Lesions in Lung. Mol Ther Nucleic Acids 2019;18:774-86. [PMID: 31734558 DOI: 10.1016/j.omtn.2019.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Thanki K, Blum KG, Thakur A, Rose F, Foged C. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities. Ther Deliv 2018;9:731-49. [PMID: 30277138 DOI: 10.4155/tde-2018-0029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
6 Taschauer A, Polzer W, Pöschl S, Metz S, Tepe N, Decker S, Cyran N, Scholda J, Maier J, Bloß H, Anton M, Hofmann T, Ogris M, Sami H. Combined Chemisorption and Complexation Generate siRNA Nanocarriers with Biophysics Optimized for Efficient Gene Knockdown and Air-Blood Barrier Crossing. ACS Appl Mater Interfaces 2020;12:30095-111. [PMID: 32515194 DOI: 10.1021/acsami.0c06608] [Reference Citation Analysis]
7 Thanki K, van Eetvelde D, Geyer A, Fraire J, Hendrix R, Van Eygen H, Putteman E, Sami H, de Souza Carvalho-Wodarz C, Franzyk H, Nielsen HM, Braeckmans K, Lehr CM, Ogris M, Foged C. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. J Control Release 2019;310:82-93. [PMID: 31398360 DOI: 10.1016/j.jconrel.2019.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
8 Mahri S, Rondon A, Wilms T, Bosquillon C, Vanbever R. Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. J Control Release 2021;329:1054-65. [PMID: 33091532 DOI: 10.1016/j.jconrel.2020.10.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]